Cardiology Update 2013 How can we better translate evidence into practice ? Davos, February 11, 2013

Secondary Prevention The ELIPS trial and beyond







François Mach Cardiology Department Geneva University Hospital Francois.Mach@hcuge.ch

www.cardiology-geneva.ch


I don't have any conflict of interest for this presentation

ACS: a poor prognosis

STEMI NSTEMI

30-Day Mortality

1-Year Mortality



GRACE Registry. Am J Cardiol <u>2004</u>;93:288 Eur Heart J <u>2007</u>;28:1409

ACS: a high rate of recurrent CV event

N=68'236 patients

Why is there a high recurrence rate?

Cardiovascular Mortality / MI / Stroke cardiovascular death, angina, PAD) within the next 12 months following an ACS.

at risk of atherothrombosis

 \cap

established atherosclerotic arterial disease


JAMA <u>2007</u>;297:1197

ACS: a poor prognosis

• Why is the recurrence rate so high?

- Under use of recommended therapy by physician
- Atherosclerosis is a chronic disease with a complex treatment
- Lack of therapeutic adhesion by the patient


Lack of adherence-compliance



Improving adherence to treatment: A target with more impact than any other treatment !

Adherence to statins

All patients aged 66 years of older from Ontario who received at least 1 statin prescription



At 6 months: > 25% stopped statins

Two-year continuous adherence rates:


- ACS: 40.1%
- chronic CAD: 36.1%
- primary prevention: 25.4%

and 303 days for overall.


Adherence to therapy

Preventive Cardiology

Efficacy of In-Hospital Multidimensional Interventions of Secondary Prevention After Acute Coronary Syndrome A Systematic Review and Meta-Analysis



The results of Therapeutic Education in chronic diseases



Time




ELIPS: a Multi-dim<u>e</u>nsional prevention program after AC<u>S</u>

Department of Cardiology Geneva University Hospital



"Acute Coronary Syndrome-Inflammation" FNS SPUM Project (www.spum-acs.ch)



Tools of information \longrightarrow comprehension and motivation of the patient by using uniform messages: <u>Patient-level intervention</u>



For hospitals and outpatient practices





Multi-dimensional

weh

ELIPS[®] HEART ATTACKS AND ATHEROSCLEROSIS Heart attack: an emergency The atherosclerosis: a chronic disease 👻 Treatment and medical follow up 🗙 🚺 💻 🚺 🈹 🛛 Main page Medical staff infos Together to fight Heart attack and Atherosclerosis Practical Health advice pamphlets Avoid the recurrence Patient's space Ethical chart For patients For Healthcare providers

EDUCATIONAL THERAPEUTIC PROGRAM TO FIGHT

ELIPS[®]

Hôpitaux Universitaires de Genève rue Gabrielle Perret-Gentil 4 (ex - 24 rue Micheli-du-Crest) 1211 Genève 14 e-mail:elips.heart@hcuge.ch

Evaluate your Cardiovascular risk



www.elips.ch



DVD



Tools of Communication


Inter-active participation







Tools of Communication





Novel information tools about ACS and Atherosclerosis:

- a standardized discharge card of treatment
- a website, an e-learning
- an educational DVD
- information flyers & wall chart

and


- symposiums of information for outpatient and physicians organized by local university hospitals

Tools offered to GPs, internists, cardiologists for their patients



ZH, BE, LS, GE: SPUM project www.spum-acs.ch ELIPS Study

Inclusion: ACS



[°] Endpoint: Adherence, CV events

2° Endpoint: Bio-clinical : BMI \downarrow , LDL \downarrow , CRP \downarrow , HDL \uparrow , tabacco, etc...

SPUM-ACS studies


STUDY SITE	BIOMARKER		Biomarker Control	Comfortable Imaging/Stent COMPLETED	ELIPS Intervention/ Control		SPUM TOTAL
	Last 7 days	Total		Total	Last 7 days	Total	
BERN	3	801		60/250	-	439/230	1,779
GENEVA	10	374		13/82	9	402/616	1,473
LAUSANNE	1	350		-	1	435/375	1,161
zн	12	1000	109*	3/45	-	205/145	1,476 (109 controls)
TOTAL	26	2520	109*	103/1161	10	1471/ 1366	5,862

Data on Monday, February 4th, 2013


Documented Recommended Treatment at Discharge of Participants Hospitalized for an ACS (2009-2010)


	Total	Unstable angina	NSTEMI	STEMI
	N=1,260	N=81	N=491	N=688
Aspirin Documentation,%	100%	100%	100%	100%
Aspirin Prescription, %	99.4 %	98.8 %	99.0%	99.7%
P2Y12 inhibitors Documentation %	99.9%	100 %	99.7%	100 %
P2Y12 inhibitors Prescription, %	99.8 %	100 %	99.5%	100%
Statins Documentation, %	98.6%	96.3%	98.0%	99.3%
Statins Prescription, %	98.0 %	95.1 %	97.4 %	98.8 %
Beta-blockers Documentation, %	96.1%	92.6%	95.3 %	97.0%
Beta-blockers Prescription, %	81.7 %	76.5 %	83.3 %	81.1 %
ATII/ACEI Documentation, % (LVEF ≤40%)	100 %	100 %	100 %	100 %
ATII /ACEI Prescription, % (LVEF ≤40%)	90.8%	85.2 %	88.2 %	93.3 %
Cardiac Rehabilitation, %	61.5%	17.3%	54.0%	72.1%


Improvement in quality of care for patients discharged after ACS over the last 10 years



Patients reaching LDL goals 1 year after an Acute Coronary Syndrome







Documented recommended treatment at discharge of participants hospitalized for an ACS (2009-2010)

	Total	Unstable angina	NSTEMI	STEMI
	N=1,260	N=81	N=491	N=688
Aspirin Documentation,%	100%	100%	100%	100%
Aspirin Prescription, %	99.4 %	98.8 %	99.0%	99.7%
P2Y12 inhibitors Documentation %	99.9%	100 %	99.7%	100 %
P2Y12 inhibitors Prescription, %	99.8 %	100 %	99.5%	100%
Statins Documentation, %	98.6%	96.3%	98.0%	99.3%
Statins Prescription, %	98.0 %	95.1 %	97.4 %	98.8 %
Beta-blockers Documentation, %	96.1%	92.6%	95.3 %	97.0%
Beta-blockers Prescription, %	81.7 %	76.5 %	83.3 %	81.1 %
ATII/ACEI Documentation, % (LVEF ≤40%)	100 %	100 %	100 %	100 %
ATII /ACEI Prescription, % (LVEF ≤40%)	90.8%	85.2 %	88.2 %	93.3 %
Cardiac Rehabilitation, %	61.5%	17.3%	54.0%	72.1%

Factors associated with attendance to cardiovascular rehabilitation among 1260 participants hospitalized for for acute coronary syndrome in 4 academic centers in Switzerland from Sept 2009 to October 2010.

	Adjusted OR (95% CI) ^{\dagger}	P value
Age		
< 65 years	Ref.	-
65 to 80 years	.6 (.4, .8)	<.001
>80 years	.3 (.2, .5)	<.001
Female gender	1.0 (.7, 1.4)	.83
Current smoking	.7 (.6, 1.0)	.05
Lower education [‡]	.7 (.5, 1.0)	.08
History of CHD	.3 (.2, .4)	<.001
Discharge diagnosis		
Unstable angina	.2 (.1, .3)	<.001
NSTEMI	.5 (.4, .7)	<.001
STEMI	Ref.	-

Improvements in quality of care for patients discharged after acute

coronary syndromes over the last 10 years

Short title: Quality of care after acute coronary syndrome

Dr Reto Auer, MD¹; Dr Baris Gencer, MD²; Dr Lorenz Räber, MD³; Dr. Roland Klingenberg, MD⁴; Dr Sebastian Carballo, MD, PhD⁵; Dr David Carballo, MD, MPH²; Dr David Nanchen, MD, MSc⁶; Pr Jacques Cornuz, MD, MPH⁶; Pr John-Paul Vader, MD, MPH⁷; Pr. Pierre Vogt, MD⁸; Pr Peter Jüni, MD⁹; Dr Christian M. Matter, MD⁴; Pr Stephan Windecker, MD³; Pr Thomas Felix Lüscher, MD⁴; Pr François Mach, MD²; Pr Nicolas Rodondi, MD, MAS¹⁰

Discontinuation of Recommended Therapies One Year after an Acute Coronary Syndrome: Results from a Prospective Cohort

B. Gencer, N. Rodondi, R. Auer, D. Carballo, L. Räber, D. Nanchen, P. Vogt, S. Carballo, P. Meyer, P.-F. Keller, C.M. Matter, S. Windecker, T.F. Lüscher, F. Mach (Geneva, Bern, San Francisco, Lausanne, Porrentruy, Zürich, CH)

Lipid-Lowering Therapy Modification and LDL-C Goal Achievement after an Acute Coronary Syndrome: A Prospective Swiss Cohort

B. Gencer, F. Mach, R. Auer, D. Carballo, L. Räber, D. Nanchen, P. Vogt, S. Carballo, P. Meyer, P.-F. Keller, C.M. Schmied, C.M. Matter, S. Windecker, T.F. Lüscher, N. Rodondi (Geneva, CH; San Francisco, US; Bern, Lausanne, Porrentruy, Zürich, CH)

www.spum-acs.ch

Thank you



Dr Lukas Altweg Dr Reto Auer Dr Vincent Barthassat Dr David Carballo Dr Sebastian Carballo Pr Jean-Claude Chevrolet Dr Pierre Chopard Mme Suzanna Convert Prof Jacques Cornuz Dr Pascal Gache Pr Alain Golay Mme Christelle Guillaume Dr Pierre-Frédéric Keller Dr Roland Klingenberg Pr Thomas Luscher Pr François Mach Dr Christian Matter

Mme Suzanne Mueller Pr Thomas Perneger Dr I orenz Raeber Mme Agnies Reffet Mme Ariel Richard-Arlaud Dr Nicolas Rodondi Dr Marco Roffi M. Allen Savard Mme Florence Scherrer M. Franck Schneider M. Philippe Sigaud Dr Johanna Sommer Pr Pierre Vogt Pr Gérard Waeber Pr Stephan Windecker



UNIVERSITÄTSSPITAL BERN HOPITAL UNIVERSITAIRE DE BERNE BERNIVIVERSITAIRE DE BERNE

Universitätsklinik für Kardiologie



UniversitätsSpital Zürich





Lack of adherence is a major problem

Improving adherence to treatment:

A target with more impact than any other treatment !

Patient-level intervention

Health care providers-level intervention

Therapeutic Education will optimalized applications of biomedical advances











Uchiyama et al. Journal of Cardiothoracic Surgery 2012, 7:26 http://www.cardiothoracicsurgery.org/content/7/1/26

JOURNAL OF CARDIOTHORACIC SURGERY


RESEARCH ARTICLE

Open Access

Auditory stimulation of opera music induced prolongation of murine cardiac allograft survival and maintained generation of regulatory CD4⁺CD25⁺ cells

Masateru Uchiyama^{1,2,3}, Xiangyuan Jin^{2,4}, Qi Zhang², Toshihito Hirai⁵, Atsushi Amano¹, Hisashi Bashuda³ and Masanori Niimi^{2*}

Conclusion: Our findings indicate that exposure to opera music, such as La traviata, could affect such aspects of the peripheral immune response as generation of regulatory CD4⁺CD25⁺ cells and up-regulation of anti-inflammatory cytokines, resulting in prolonged allograft survival.



Quid du chocolat...

